Surveillance strategies after definitive therapy of invasive bladder cancer. - Wikidata - awgldk - TriplyDB

Surveillance strategies after definitive therapy of invasive bladder cancer.

Surveillance strategies after definitive therapy of invasive bladder cancer.

http://www.wikidata.org/entity/Q37472555

about

Rational or rationing? Justifying follow-up after management of kidney cancer.Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.A smoking cessation program as a resource for bladder cancer patients.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Rare Occurrence of a Poorly Differentiated Neuroendocrine Tumor of the Bladder.Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.A case of isolated rectal recurrence of muscle invasive bladder cancer.Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

P2860

Q34179275-4FCEA516-2EDC-4ABD-A127-23737458379B Q36278425-5CB27EB7-8EE2-43A7-A888-7BDBB5F5512A Q36338956-7758C49A-EFC2-4903-9351-9494CCC912B2 Q37475193-34A0027F-D08B-4364-A1D6-FDF012CAD37F Q37587337-730C0B37-C847-48D9-B6E0-2FB96AA822C8 Q38842793-27835E00-3631-49E1-B704-048CE8C802F1 Q41255730-7223EB98-C246-41EA-90D0-7119683A50F0 Q49508672-F45996E7-0D45-4F6D-BE10-CB391C366CB7

P2860

Surveillance strategies after definitive therapy of invasive bladder cancer.

http://www.wikidata.org/entity/Q37472555

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Surveillance strategies after definitive therapy of invasive bladder cancer.

@en

Surveillance strategies after definitive therapy of invasive bladder cancer.

@nl

type

label

Surveillance strategies after definitive therapy of invasive bladder cancer.

@en

Surveillance strategies after definitive therapy of invasive bladder cancer.

@nl

prefLabel

Surveillance strategies after definitive therapy of invasive bladder cancer.

@en

Surveillance strategies after definitive therapy of invasive bladder cancer.

@nl

P1433

Q37472555-04EE9B86-0FA2-4FFF-9E4A-780EE8715EF0

P1476

Q37472555-41FE34F1-B3A1-4869-827B-848AD944E00E

P2093

Q37472555-D71FC65C-C45B-43A8-8144-7EC0ACFEBAC0

Q37472555-E242F30D-D28D-4E9F-928F-87902881A9DE

P2860

Q37472555-054B48AB-E84C-4ACF-99DF-3A3302311BA5

Q37472555-2A375322-F6E0-4498-AF87-76ACD682EC23

Q37472555-32BE00AC-1B75-4C2A-802E-47AC50E5EC42

Q37472555-434B9DC2-893A-47A3-A828-C3E8BB0AB109

Q37472555-4831748D-73A3-40FB-BE6A-213BD9D03633

Q37472555-4B480E00-E5D8-47B1-8545-5FB7C5622F9D

Q37472555-507D48FA-1B01-4E9C-BB83-FCC6A70ECEB9

Q37472555-50C1D2AD-AD7F-449B-BA6E-F4D095BF73CF

Q37472555-6054049E-35A5-4F01-A12D-E7B97DE67653

Q37472555-665C71CA-0F63-41D4-B886-7AEB35AB469A

P304

Q37472555-EB8D8381-B898-44B5-AD3F-B6915D4E79EA

P31

Q37472555-B2DD48E6-B5C5-47F3-A79B-A072D6641478

P433

Q37472555-3CE9A2C4-E5B8-45AF-A914-B84892583F8C

P478

Q37472555-9F72F9A6-570F-44F1-819A-1A4724CF2B97

P577

Q37472555-4DD35451-BBC9-4241-A0BB-A11508EC2893

P698

Q37472555-2D66F50A-6EF7-45F8-B75C-3B7D86C6D54D

P932

Q37472555-39D79188-C43A-4314-B2B3-A2FBA034F277

P1433

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

P1476

Surveillance strategies after definitive therapy of invasive bladder cancer.

@en

P2093

Christopher Morash

http://www.w3.org/2001/XMLSchema#string

Ilias Cagiannos

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Cancer statistics, 2005

Urinary diversion-related outcome in patients with pelvic recurrence after radical cystectomy for bladder cancer.

Upper tract transitional cell carcinoma following cystectomy for bladder cancer.

Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer.

Upper tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: incidence and risk factors.

Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments.

Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature.

Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance.

Bladder preservation: optimizing radiotherapy and integrated treatment strategies.

P304

S237-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

6 Suppl 4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20019993

http://www.w3.org/2001/XMLSchema#string

P932

2792448

http://www.w3.org/2001/XMLSchema#string